Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00194792 · ClinicalTrials.gov registry record · Phase 2
Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00194792 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 28 participants.
The verdict
NCT00194792, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This phase II trial is studying how well giving hormone therapy together with combination chemotherapy before and after surgery works in treating patients with stage I-IIIA breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane and triptorelin pamoate may fight breast cancer by lowering the amount of estrogen the body makes. Drugs used in chemotherapy, such as capecitabine, methotrexate, vinorelbine ditartrate, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving hormone therapy together with combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments after surgery may kill any tumor cells that remain after surgery
Interventions
- DRUG capecitabine
- DRUG exemestane
- DRUG methotrexate
- DRUG vinorelbine tartrate
- DRUG triptorelin pamoate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2005-08 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00194792
The ClinicalTrials.gov registry entry for NCT00194792 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which capecitabine is the first listed.
NCT00194792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00194792 about?
NCT00194792 is a clinical study titled "Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer". This phase II trial is studying how well giving hormone therapy together with combination chemotherapy before and after surgery works in treating patients with stage I-IIIA breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane and triptorelin pamoate m...
What is the current status of trial NCT00194792?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2005-08. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00194792?
The interventions under investigation include: capecitabine (DRUG), exemestane (DRUG), methotrexate (DRUG), vinorelbine tartrate (DRUG), triptorelin pamoate (DRUG).
Who is sponsoring clinical trial NCT00194792?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.